The 2009 Frost & Sullivan South Africa Company of the Year Award in the Generic Pharmaceutical Market is presented to Cipla Medpro South Africa Limited.
For the Company of the Year Award, the following criteria were used to benchmark Cipla Medpro's performance against key competitors: growth strategy and implementation, degree of innovation in business processes, products and/or technologies and leadership in customer value and market penetration.
"The company's growth strategy is displayed in both its expanding geographic footprint as well as the diversification of its unique product mix," notes Frost & Sullivan Research Analyst Jolize Gerber. "The company is growing its South African business by concentrating its efforts on establishing a stronger presence in the local market across numerous therapeutic categories as well as the fast-growing Over The Counter market and, despite adverse market conditions, has enjoyed a solid recent performance in the past year."
The company has exhibited continued growth in its existing products and reveals a strong pipeline of new products. This has given Cipla Medpro a competitive advantage over other companies in the market leading to it being the fastest growing pharmaceutical company by value over the past three years according to IMS statistics.
Cipla Medpro has displayed continued innovation of business processes to maintain growth in a very competitive and complex market. One example is the strategic partnership formed with Cipla Ltd in India, which entails a 20 year supply and manufacturing agreement. This partnership has enabled Cipla Medpro to gain access to R&D, resources and opportunities as well as the established, trusted brand name offered by Cipla Ltd.
"Cipla Medpro creates and maintains strong brands by ensuring a robust pipeline of novel, high potential products, and by providing ongoing promotions and market support," adds Gerber. "These efforts support Cipla Medpro in growing its market share in the South African market."
The company enjoys leadership in customer value by offering competitive pricing of high quality products. It has ensured that its production plant meets international Pharmaceutical Inspection Convention Standards and the quality of its products is benchmarked against international standards.
Efficient distribution and ongoing marketing support has ensured that the Cipla Medpro brand is associated with efficiency and reliability. Furthermore, Cipla Medpro creates customer value by addressing the key challenges within the South African market.